Abstract | BACKGROUND:
AS602801, a novel inhibitor of c-Jun N-terminal kinase (JNK), suppresses tumor initiation capacity and metastatic potential of cancer stem cells (CSCs). However, it remains unknown whether this inhibitor can chemosensitize CSCs. MATERIALS AND METHODS: RESULTS: CONCLUSION:
AS602801, which reduces survivin expression, can chemosensitize ovarian CSCs and is a candidate drug that targets the chemoresistance, tumor-initiating capacity and metastasis of CSCs.
|
Authors | Masahiro Yamamoto, Shuhei Suzuki, Keita Togashi, Tomomi Sanomachi, Shizuka Seino, Chifumi Kitanaka, Masashi Okada |
Journal | Anticancer research
(Anticancer Res)
Vol. 38
Issue 12
Pg. 6699-6706
(Dec 2018)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 30504379
(Publication Type: Journal Article)
|
Copyright | Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. |
Chemical References |
- Benzothiazoles
- Pyrimidines
- Survivin
- Carboplatin
- Paclitaxel
- bentamapimod
|
Topics |
- A549 Cells
- Benzothiazoles
(pharmacology)
- Carboplatin
(pharmacology)
- Cell Line, Tumor
- Drug Resistance, Neoplasm
(drug effects, genetics)
- Drug Synergism
- Female
- Gene Expression Regulation, Neoplastic
(drug effects)
- Humans
- Neoplastic Stem Cells
(drug effects, metabolism, pathology)
- Ovarian Neoplasms
(pathology)
- Paclitaxel
(pharmacology)
- Pyrimidines
(pharmacology)
- Survivin
(genetics, metabolism)
|